Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-08-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2021年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021 Semi-Annual Special Report on the Deposit and Actual Use of Raised Funds" by Shenzhen BGI Genomics Co., Ltd. It details the use and management of funds raised through a specific stock issuance, including amounts raised, usage, investment projects, and compliance with regulatory guidelines. The document includes detailed financial figures related to the raised funds, their allocation, and usage during the first half of 2021. It is a specialized report focusing on the management and use of capital raised, not a general financial report like an annual or interim report. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is sufficient and contains substantive financial data about the fundraising and use of proceeds, not merely an announcement or certification. Therefore, the appropriate classification is CAP.
2021-08-26 Chinese
2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳华大基因股份有限公司 2021 年半年度报告全文" which translates to "BGI Genomics Co., Ltd. 2021 Semi-Annual Report Full Text." It explicitly states the report period as January 1, 2021 to June 30, 2021, indicating it is a half-year financial report. The content includes detailed sections such as company overview, management discussion and analysis, governance, environmental and social responsibility, financial data, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, which is substantial and contains actual financial data and analysis, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-26 Chinese
关于拟参与投资设立合伙企业暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by Shenzhen BGI Genomics Co., Ltd. regarding its planned investment in establishing a partnership enterprise and related party transaction. It includes extensive information about the investment fund, the partners, financial data of the partners, the investment purpose, necessity, risks, and impact on the company. The document is a formal disclosure of a capital investment transaction involving related parties, with detailed descriptions of the investment structure, fund management, and governance. It does not contain financial statements or quarterly/yearly financial results, nor is it a transcript, audit report, or governance report. It is not a report publication announcement or a certification. The content fits best with a Capital/Financing Update (CAP) as it concerns the company's fundraising and capital structure changes through investment in a fund and related party transactions.
2021-08-26 Chinese
关于因同一实际控制人控制下关联方深圳华大智造科技股份有限公司科创板上市信息披露需要相应披露相关明细经营信息的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding disclosure of detailed operating information related to its related party Shenzhen BGI Manufacturing Technology Co., Ltd. in connection with the latter's initial public offering and listing on the STAR Market (科创板). The document includes extensive financial and operational data from 2018 to 2020, explanations of related party transactions, product sales, procurement details, and clarifications on business operations and competition. It is not a full annual or interim report, nor is it a simple announcement of a report. It is a regulatory disclosure related to compliance with listing rules and information disclosure requirements for a related party's IPO. The document does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement providing detailed compliance and disclosure information, which aligns best with the category Regulatory Filings (RNS). The document length (9960 characters) and content support this classification rather than a report publication announcement or other categories.
2021-08-22 Chinese
关于子公司签署国有建设用地使用权出让合同的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding its subsidiary signing a state-owned construction land use rights transfer contract. It details the transaction overview, contract terms, and the impact on the company. The document is relatively short (1749 characters) and focuses on a specific land use rights contract, which is a capital asset transaction. It does not contain financial statements or comprehensive financial data, nor is it a report or presentation. It is an announcement about a capital asset acquisition and contract signing, which fits best under Capital/Financing Update (CAP).
2021-08-20 Chinese
关于独立董事取得独立董事资格证书的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from Shenzhen BGI Genomics Co., Ltd. regarding an independent director, Ms. Du Lan, obtaining her independent director qualification certificate. It references a shareholder meeting where she was elected and confirms compliance with Shenzhen Stock Exchange disclosure guidelines. The content focuses on board/management information, specifically about a director's qualification status. It is not a financial report, earnings release, or regulatory filing of financial data. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a Director's Dealing report as it does not mention share transactions.
2021-08-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.